Le S Q, Wasserstrum N, Mombouli J V, Vanhoutte P M
Department of Obstetrics/Gynecology, Baylor College of Medicine, Houston, TX 77030.
Am J Obstet Gynecol. 1993 Oct;169(4):919-24. doi: 10.1016/0002-9378(93)90027-g.
The aim was to study the effects of endothelin-1 on human placental veins and the role of cyclooxygenase products as mediators of these effects.
Rings of placental veins with and without endothelium were suspended in organ chambers filled with physiologic salt solution. After a period of stabilization at optimal basal tension, isometric tensions in the control group were recorded at increasing concentrations of endothelin-1 (10(-10) to 10(-7) mol/L). Rings in the experimental groups were treated with either indomethacin (cyclooxygenase inhibitor, 10(-5) mol/L), dazoxiben (thromboxane synthetase inhibitor, 10(-4) mol/L), or SQ29548 (thromboxane receptor antagonist, 10(-6) mol/L) before addition of endothelin-1. To demonstrate the presence of functional thromboxane receptors in the rings, contractile responses to U-46619 (10(-9) to 10(-6) mol/L), a thromboxane A2 analog were measured. The effectiveness of SQ29548 blockade was tested in rings treated with SQ29548 (10(-6) mol/L) before addition of U-46619. The concentration-response curves of the treated and control groups were compared with the Student paired t test.
Endothelin-1 in doses of 10(-10) to 10(-7) mol/L caused concentration-dependent contraction of placental veins. Indomethacin significantly reduced the response of veins with endothelium to low endothelin-1 concentrations (10(-9.5) to 10(-9) mol/L), (p < 0.05). However, it had no effect at higher endothelin-1 concentrations or in vessels without endothelium. The presence of functional thromboxane A2 receptors was confirmed by the vasoconstrictor effect of U-46619 and its blockade by treatment with SQ29548. Neither SQ29548 nor the thromboxane A2 synthesis inhibitor dazoxiben significantly influenced the response to endothelin-1.
These results demonstrated that endothelin-1 is a potent vasoconstrictor in the human placental vein. Although functional thromboxane A2 receptors exist in this vessel, endothelin-1's action is independent of thromboxane A2. Prostaglandins may mediate part of the endothelin-1-induced placental vasoconstriction. However, endothelin-1 acts primarily by a direct effect on vascular smooth muscle cells.
本研究旨在探讨内皮素-1对人胎盘静脉的作用,以及环氧化酶产物作为这些作用介质的角色。
将有内皮和无内皮的胎盘静脉环悬挂于充满生理盐溶液的器官浴槽中。在最佳基础张力下稳定一段时间后,记录对照组在不同浓度内皮素-1(10⁻¹⁰至10⁻⁷mol/L)作用下的等长张力。实验组的静脉环在加入内皮素-1之前,分别用吲哚美辛(环氧化酶抑制剂,10⁻⁵mol/L)、达唑氧苯(血栓素合成酶抑制剂,10⁻⁴mol/L)或SQ29548(血栓素受体拮抗剂,10⁻⁶mol/L)进行处理。为证明静脉环中存在功能性血栓素受体,测量对血栓素A2类似物U-46619(10⁻⁹至10⁻⁶mol/L)的收缩反应。在加入U-46619之前,检测用SQ29548(10⁻⁶mol/L)处理的静脉环中SQ29548阻断的有效性。用学生配对t检验比较处理组和对照组的浓度-反应曲线。
10⁻¹⁰至10⁻⁷mol/L剂量的内皮素-1可引起胎盘静脉浓度依赖性收缩。吲哚美辛显著降低了有内皮静脉对低浓度内皮素-1(10⁻⁹.⁵至10⁻⁹mol/L)的反应(p<0.05)。然而,在较高浓度内皮素-1时或对无内皮的血管,它没有作用。U-46619的血管收缩作用及其被SQ29548处理阻断,证实了功能性血栓素A2受体的存在。SQ29548和血栓素A2合成抑制剂达唑氧苯均未显著影响对内皮素-1的反应。
这些结果表明,内皮素-1是一种强力的人胎盘静脉血管收缩剂。尽管该血管中存在功能性血栓素A2受体,但内皮素-1的作用独立于血栓素A2。前列腺素可能介导了部分内皮素-1诱导的胎盘血管收缩。然而,内皮素-1主要通过直接作用于血管平滑肌细胞发挥作用。